IMNN:NASDAQImunon, Inc. Analysis
Data as of 2026-05-19 - not real-time
$2.26
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Imunon, Inc. (IMNN) trades at $2.26, well below its 20‑day SMA of $2.73 and 50‑day SMA of $2.90, and far under the 200‑day SMA of $4.12, indicating a strong bearish price bias. The RSI of 20.8 suggests the stock is oversold, while the MACD line sits below its signal (‑0.136 vs ‑0.098) reinforcing bearish momentum. Technical support sits at $2.22 with resistance near $3.15, and volatility is elevated at ~44% over the past 30 days, compounded by a historic max drawdown of 93%.
Despite these price pressures, recent company communications highlight continued advancement of the Phase 3 OVATION 3 trial for IMNN‑001, a potential breakthrough in advanced ovarian cancer, and the firm is actively exploring financing options to fund its pipeline, which aligns with analyst consensus of a “strong buy” and a median price target of $16.
Despite these price pressures, recent company communications highlight continued advancement of the Phase 3 OVATION 3 trial for IMNN‑001, a potential breakthrough in advanced ovarian cancer, and the firm is actively exploring financing options to fund its pipeline, which aligns with analyst consensus of a “strong buy” and a median price target of $16.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below all major moving averages
- Oversold RSI but high volatility
- Proximity to technical support at $2.22
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Advancing Phase 3 OVATION 3 trial data expected
- Analyst consensus strong‑buy with median target $16
- Current price offers >600% upside potential
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Potential first‑line immunotherapy in ovarian cancer
- Pipeline diversification into COVID‑19 booster and other DNA‑based therapies
- Undervalued valuation relative to long‑term target price
Key Metrics & Analysis
Financial Health
P/E Ratio-1.2
ROE-768.20%
ROA-124.43%
Debt/Equity27.14
P/B Ratio3.4
Industry P/E26.9
Technical Analysis
TrendBearish
RSI20.8
Support$2.22
Resistance$3.15
MA 20$2.73
MA 50$2.90
MA 200$4.12
MACDBearish
VolumeIncreasing
Fear & Greed Index89.61
Valuation
Target Price$17.60
Upside/Downside678.76%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.11
Volatility43.97%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.